SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Cancer Research UK. Risks and causes of anal cancer. Available at: http://cancerhelp.cancerresearchuk.org/type/anal-cancer/about/risks-and-causes-of-anal-cancer. Accessed May 20, 2012.
  • 2
    Boman BM, Moertel CG, O'Connell MJ, et al. Carcinoma of the anal canal. A clinical and pathologic study of 188 cases. Cancer. 1984; 54: 114-125.
  • 3
    Bilimoria KY, Bentrem DJ, Rock CE, et al. Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base. Dis Colon Rectum. 2009; 52: 624-631.
  • 4
    Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil and mitomycin. UKCCCR Anal Cancer Working Party. UK Co-ordinating Comimittee on Cancer Research. Lancet. 1996; 348: 1049-1054.
  • 5
    Northover J, Glynne-Jones R, Sebag-Montefiore D, et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer. 2010; 102: 1123-1128.
  • 6
    Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997; 15: 2040-2049.
  • 7
    Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996; 14: 2527-2539.
  • 8
    Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin and radiotherapy vs fluorouracil, cisplatin and radiotherapy for carcinoma of the anal canal: a randomised controlled trial. JAMA. 2008; 199: 1914-1921.
  • 9
    Peiffert D, Tournier-Rangeard L, Gerard JP, et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 Trial. J Clin Oncol. 2012; 30: 1941-1948.
  • 10
    James R, Wan S, Glynne-Jones R, et al. A randomised trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus [abstract]. J Clin Oncol. 2009; 27: 18S( pt II of II). Abstract LBA-4009.
  • 11
    Gunderson LL, Winter KA, Ajani JA, et al. Long-term update of US GI Intergroup RTOG 98-11 phase III trial for anal carcinoma: comparison of concurrent chemoradiation with 5FU-mitomycin versus 5FU-cisplatin for disease-free and overall survival [abstract]. J Clin Oncol. 2011; 29(suppl 4). Abstract 367.
  • 12
    Ajani JA, Winter KA, Gunderson LL, et al. Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). Cancer. 2010; 116: 4007-4013.
  • 13
    Spiessl B, Hermanek P, Scheibe O, Wagner G, eds. TNM-Atlas: Illustrated Guide to the TNM/pTNM-Classification of Malignant Tumours. 2nd ed. Berlin: Springer-Verlag; 1985.
  • 14
    Royston P, Moons KGM, Altman DG, Vergouwe Y. Prognosis and prognostic research: developing a prognostic model. BMJ. 2009; 338: 1373-1377.
  • 15
    Altman DG, Vergouwe Y, Royston P, Moons KGM. Prognosis and prognostic research: validating a prognostic model. BMJ. 2009; 338: 1432-1435.
  • 16
    Cummings BJ, Keane TJ, O'sullivan B, et al. Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin. Int J Radiat Oncol Biol Phys. 1991; 21: 1115-1125.
  • 17
    Das P, Bhatia S, Eng C, et al. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys. 2007; 68: 794-800.
  • 18
    Touboul E, Schlienger M, Buffat L, et al. Epidermoid carcinoma of the anal canal. Results of curative-intent radiation therapy in a series of 270 patients. Cancer. 1994; 73: 1569-1579.
  • 19
    Peiffert D, Bey P, Pernot M, et al. Conservative treatment by irradiation of epidermoid cancers of the anal canal: prognostic factors of tumoral control and complications. Int J Radiat Oncol Biol Phys. 1997; 37: 313-324.
  • 20
    Myerson RJ, Kong F, Birnbaum EH, et al. Radiation therapy for epidermoid carcinoma of the anal canal, clinical and treatment factors associated with outcome. Radiother Oncol. 2001; 61: 15-22.
  • 21
    Grabenbauer GG, Kessler H, Matzel KE, et al. Tumor site predicts outcome after radiochemotherapy in squamous-cell carcinoma of the anal region: long-term results of 101 patients. Dis Colon Rectum. 2005; 48: 1742-1751.
  • 22
    Constantinou EC, Daly W, Fung CY, Willett CG, Kaufman DS, DeLaney TF. Time-dose considerations in the treatment of anal cancer. Int J Radiat Oncol Biol Phys. 1997; 39: 651-657.
  • 23
    Roldan GB, Chan AK, Buckner M, Magliocco AM, Doll CM. The prognostic value of hemoglobin in patients with anal cancer treated with chemoradiotherapy. Dis Colon Rectum. 2010; 53: 1127-1134.
  • 24
    Hoff CM. Importance of hemoglobin concentration and its modification for the outcome of head and neck cancer patients treated with radiotherapy. Acta Oncol. 2012; 51: 419-432.
  • 25
    McMillan D. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 2009; 12: 223-226.
  • 26
    Mabuchi S, Matsumoto Y, Isohashi F, et al. Pretreatment leukocytosis is an indicator of poor prognosis in patients with cervical cancer. Gynecol Oncol. 2011; 122: 25-32.
  • 27
    Spiessl B, Hermanek P, Scheibe O, Wagner G, eds. Union Internationale Contre Le Cancer (UICC) TNM-Atlas Illustrated Guide to the TNM/pTNM-Classification of Malignant Tumours, 4th ed. Berlin: Springer-Verlag; 1990.